BeOne Medicines posts strong Q3 2026 results and lifts full‑year revenue outlook
BeOne Medicines reported third‑quarter 2026 revenue of $1.89 billion, a 34% year‑over‑year increase, and GAAP diluted earnings of $3.28 per ADS. The company raised its full‑year revenue guidance to $6.9 billion‑$7.0 billion and highlighted Brukinsa U.S. sales surpassing $1 billion. Management noted robust regional growth, especially in China, Europe and the rest of the world, while warning of competitive pressure on XGEVA and KYPROLIS after 2026.
Why it matters
The raised guidance signals higher expected cash flow and may support a higher valuation; Jefferies responded by lifting its price target to $470 from $410. The revenue beat and strong margin expansion also improve the company’s financial health perception among investors.
Key facts
- 1Q3 2026 revenue was $1.89 billion, up 34% YoY. tradingview.com
- 2GAAP diluted earnings were $3.28 per ADS. tradingview.com
- 3Full‑year 2026 revenue guidance was increased to $6.9 billion‑$7.0 billion. tradingview.com
- 4Brukinsa U.S. sales exceeded $1 billion in the quarter. finance.yahoo.com
- 5Regional revenue growth: China +21% ($527 million), Europe +41% ($234 million), Rest of world +58% ($80 million). finance.yahoo.com
- 6Q3 EPS of $4.55 beat estimates by $2.66. investing.com
Open questions
- Material 4 reports Q3 revenue of $1.86 billion, conflicting with the $1.89 billion figure in material 1.
Summary written by AlphAI AI Desk from 5 of 6 sources. Not investment advice. Figures are as stated by the linked sources.